Clinical Trials Logo

Carcinoma, Neuroendocrine clinical trials

View clinical trials related to Carcinoma, Neuroendocrine.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 5

NCT ID: NCT01298323 Active, not recruiting - Clinical trials for Medullary Thyroid Cancer

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

88
Start date: February 25, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib

NCT ID: NCT00436735 Active, not recruiting - Colorectal Cancer Clinical Trials

Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors.

NCT ID: NCT00410761 Active, not recruiting - Thyroid Cancer Clinical Trials

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Start date: November 30, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

NCT ID: NCT00381641 Active, not recruiting - Clinical trials for Recurrent Thyroid Gland Carcinoma

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Start date: August 8, 2006
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.